Abundnz offers advanced analytical support for biotechnology and diagnostics industries and life science research worldwide. With the use of mass spectrometry, we characterize innovative medicines like peptide and protein drugs, oligonucleotides and targeted drug delivery systems and we discover and validate biomarkers. Abundnz has a unique technology to determine the clearance profile of innovative medicines in an early phase of drug development. Benefits are a reduction of costs, a faster time-to-market and a safer testing of biopharmaceuticals.